Coronary Artery Bypass Graft (CABG) Surgery Products Market Outlook:
Coronary Artery Bypass Graft (CABG) Surgery Products Market size is valued at USD 2.67 billion in 2026 and is projected to reach USD 4.09 billion by 2036, growing at a CAGR of 4.37% from 2027 to 2036. In 2027, the industry size of coronary artery bypass graft surgery products assessed to reach USD 2.78 billion.
The rising global burden of coronary artery disease (CAD) is mainly fueling the trade of CABG surgery products. According to the U.S. Centers for Disease Control and Prevention (CDC), coronary heart disease is the most common form of heart disease. About 5% of adults aged 20 and older in the U.S. have this condition. Each year, around 805,000 Americans experience a heart attack; roughly 605,000 are first-time events and about 200,000 occur in people who have previously had one.
Approximately one in five heart attacks is silent, meaning the person suffers heart damage without realizing it. As the number of patients with advanced or symptomatic CAD increases, demand for coronary revascularization procedures, including CABG, is also set to boom. Several interconnected risk factors are contributing to the growing CAD patient population.
Key Coronary Artery Bypass Graft (CABG) Surgery Products Market Insights Summary:
Regional Highlights:
- North America is projected to command a 33.9% share of the coronary artery bypass graft surgery products market by 2036, strengthened by a high coronary artery disease burden, an aging population, advanced cardiac-care infrastructure, and strong healthcare expenditure
- Europe is expected to account for a 28.5% share through 2036, supported by a substantial coronary artery disease burden, an aging population, and established cardiovascular healthcare systems
Segment Insights:
- The graft products segment is projected to capture a 53.2% share of the coronary artery bypass graft surgery products market through 2036, driven by the growing prevalence of multivessel coronary artery disease
- The hospital segment is anticipated to secure a 54.1% share through 2036, bolstered by the increasing burden of coronary artery disease and the specialized infrastructure required for CABG procedures
Key Growth Trends:
- Aging global population
- Increasing healthcare expenditure and cardiac infrastructure
Major Challenges:
- Stringent regulatory and reimbursement requirements
- High cost of advanced CABG equipment
Key Players: Getinge AB (Sweden),Terumo Cardiovascular Systems Corporation (U.S.),Medtronic (Ireland),LeMaitre Vascular, Inc. (U.S.),B. Braun SE (Germany),Johnson & Johnson (U.S.),Zimmer Biomet Holdings, Inc. (U.S.),Scanlan International, Inc. (U.S.).
Global Coronary Artery Bypass Graft (CABG) Surgery Products Market Forecast and Regional Outlook:
Market Size & Growth Projections:
- 2026 Market Size: USD 2.67 billion
- 2027 Market Size: USD 2.78 billion
- Projected Market Size: USD 4.09 billion by 2036
- Growth Forecasts: 4.37% CAGR (2027-2036)
Key Regional Dynamics:
- Largest Region: North America (33.9% Share by 2036)
- Fastest Growing Region: Asia Pacific
- Dominating Countries: United States, China, Japan, Germany, United Kingdom
- Emerging Countries: India, South Korea, Australia, Italy, France
Last updated on : 24 September, 2026
Coronary Artery Bypass Graft (CABG) Surgery Products Market - Growth Drivers and Challenges
Growth Drivers
- Aging global population: The increasing aging population globally is propelling the sales of CABG surgery products. This demographic is more susceptible to chronic disorders, including cardiovascular diseases. According to the World Health Organization (WHO), by 2050, around 80% of the world’s older population is expected to reside in low- and middle-income countries. Between 2015 and 2050, the share of people aged 60 and above is projected to nearly double, rising from 12% to 22% of the global population. The rising life expectancy and the expanding proportion of elderly people across developed and emerging economies directly fuel the number of patients requiring diagnosis, treatment, and long-term management. All these factors directly propel the trade of CABG surgery technologies.
- Increasing healthcare expenditure and cardiac infrastructure: The increasing healthcare expenditure and investment in cardiac-care infrastructure are creating favorable conditions for the global CABG surgery product manufacturers. Governments and healthcare organizations are expanding spending on cardiovascular diagnosis and treatment as cardiovascular diseases place a substantial burden on healthcare systems. In February 2026, Rochester General Hospital reopened a modernised cardiac catheterisation laboratory after a USD 1.5 million upgrade. The facility supports safer and more efficient heart procedures, with its cardiac teams performing over 5,600 procedures each year across four labs.
- Growing demand for effective treatment of complex coronary disease: The growing prevalence of complex coronary artery disease is supporting continued demand for CABG surgery products. During CABG procedures, surgeons may use arterial or venous grafts to create alternative pathways around blocked coronary arteries. This creates demand for products used in vessel harvesting, graft preparation, tissue stabilization, anastomosis, perfusion, and surgical closure. Growing recognition of the importance of durable revascularization is also driving adoption of arterial grafting solutions.
Challenges
- Stringent regulatory and reimbursement requirements: Stringent regulatory and reimbursement requirements restrain the growth of the global coronary artery bypass graft surgery products market. CABG products are used in complex and high-risk cardiovascular procedures, requiring manufacturers to meet rigorous standards for safety and performance. Extensive testing and obtaining regulatory authorization before commercializing new products not only increase the cost of the product but delays market introduction. To overcome such challenges, some market players are adapting approval, pricing, and market-access strategies in individual regions.
- High cost of advanced CABG equipment: The high cost of advanced CABG equipment is limiting their adoption to some extent. The integration of advanced technologies and specific materials increases the final costs of the product. Many small end users refrain from investing in these advanced CABG technologies owing to budget constraints. However, mass production is expected to aid key players in overcoming this issue.
Coronary Artery Bypass Graft (CABG) Surgery Products Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2026 |
|
Forecast Year |
2027-2036 |
|
CAGR |
4.37% |
|
Base Year Market Size (2026) |
USD 2.67 billion |
|
Forecast Year Market Size (2036) |
USD 4.09 billion |
|
Regional Scope |
|
Coronary Artery Bypass Graft (CABG) Surgery Products Market Segmentation:
Product Segment Analysis
The graft products segment is projected to capture 53.2% of the coronary artery bypass graft surgery products market share throughout the forecast period. this is due to the fact that grafts are the fundamental components used to bypass blocked or narrowed coronary arteries and restore blood flow to the heart. According to the National Library of Medicine, coronary artery disease affects roughly 16.8 million people in the U.S., and about 8 million of them have previously suffered a heart attack. The condition imposes an estimated annual economic cost of USD 165.4 billion when both direct medical expenses and indirect losses are considered. Thus, the growing prevalence of multivessel coronary artery disease is strengthening demand for graft products.
End user Segment Analysis
The hospital segment is expected to account for 54.1% of the global coronary artery bypass graft surgery products market share throughout the forecast period. The majority of complex cardiovascular surgeries are performed in hospitals. Also, hospitals provide the specialized infrastructure required to perform coronary artery bypass grafting, which makes them the most preferred treatment facility by patients. A 2023 study cited by the National Library of Medicine estimates that over 1 million heart surgeries are performed worldwide each year. In high-income countries, the average rate is about 123 cardiac operations per 100,000 people annually. Thus, the increasing burden of coronary artery disease is further strengthening hospital demand for CABG products.
Procedure Type Segment Analysis
The other procedure type segment is set to hold 82.7% of the global coronary artery bypass graft surgery products market share through 2036. This is because CABG procedures encompass a broad range of surgical approaches beyond the major conventional classifications. This category includes specialized and hybrid approaches, combined revascularization procedures, and less frequently performed techniques. The diversity of these procedures creates a broad product requirement across the segment.
Our in-depth analysis of the coronary artery bypass graft (CABG) surgery products market includes the following segments:
|
Segments |
Subsegments |
|
Product |
|
|
End user
|
|
|
Procedure Type |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Coronary Artery Bypass Graft Devices (CABG) Surgery Products Market - Regional Analysis
North America Market Insights
The North America coronary artery bypass graft surgery products market is projected to hold a 33.9% share through 2036. The coronary artery bypass graft surgery products market is supported by a high burden of coronary artery disease and an aging population. The advanced cardiac-care infrastructure and strong healthcare expenditure are propelling the sales of coronary artery bypass graft surgery products. Technological innovations are also promoting the development of coronary artery bypass graft surgery products.
The U.S. coronary artery bypass graft surgery products market is estimated to be valued at USD 880,248.89 thousand in 2027. The country’s large healthcare system and extensive network of cardiovascular hospitals are propelling the trade of CABG surgery products. The advanced surgical capabilities and substantial spending on cardiovascular care are further set to double the revenues of key players in the years ahead.
Canada represents a smaller but well-established market for CABG surgery products. The coronary artery bypass graft surgery products market is projected to reach USD 182,147.86 thousand by 2036. The country’s publicly funded healthcare system and specialized cardiac centers are further pushing the trade of CABG surgery products. According to the Heart and Stroke Foundation of Canada, about nine in ten Canadians have at least one factor that raises their risk of heart disease, stroke, or vascular cognitive impairment. Thus, the rising prevalence of cardiovascular disease remains a key growth driver.
Europe Market Insights
Europe is estimated to hold 28.5% of the global coronary artery bypass graft surgery products market share throughout the forecast period. The market is supported by a substantial burden of coronary artery disease and an aging population. The established cardiovascular healthcare systems and widespread availability of specialized cardiac surgery centers contribute to the overall market growth. Germany, the UK, France, Italy, and Spain are some of the key marketplaces for CABG surgery product manufacturers.
The Germany coronary artery bypass graft surgery products market is set to reach USD 198,949.84 thousand through 2036. The market is supported by its large healthcare system and extensive hospital infrastructure. The well-developed cardiovascular care capabilities also promote the trade of CABG surgery products. Further, the German market benefits from advanced medical technology adoption and a strong emphasis on clinical quality.
The UK represents a significant European coronary artery bypass graft surgery products market, supported primarily by the National Health Service (NHS). The market is poised to be valued at USD 143,041.35 thousand in 2026. Further, the country’s specialized cardiac centers and established cardiovascular treatment pathways fuel the adoption of CABG surgery products.
Asia Pacific Market Insights
Asia Pacific is anticipated to hold a share of 26.9% of the global market by the end of 2036. The market is expanding as cardiovascular disease becomes a growing healthcare concern across both developed and emerging economies. The increasing prevalence of coronary artery disease, population aging, and urbanization is fueling the trade of coronary artery bypass graft surgery products. Countries such as China, Japan, India, South Korea, and Australia are the most profitable for advanced cardiac care technology manufacturers.
India represents an attractive growth space for CABG surgery product manufacturers, with the market estimated to reach USD 232,463.97 thousand by 2036. The country’s large population and increasing cardiovascular disease burden are pushing the trade of CABG surgery products. Over the past 12 years, the Government of India has expanded healthcare access by providing health cover to more than 44 crore families and establishing over 1.86 lakh primary healthcare centres. The expanding private and public healthcare infrastructure is pushing the trade of CABG surgery products.
Japan’s coronary artery bypass graft surgery products market is projected to reach USD 177,336.80 thousand by 2036. The market is supported by its advanced healthcare infrastructure and high medical technology adoption. The rapidly aging population is the key factor boosting the demand for coronary artery bypass graft surgery products. According to the World Bank Open Data, nearly 30% of the population of Japan is aged 60 and above. The country's demographic structure is particularly important because older adults have a higher incidence of coronary artery disease and are more likely to require complex cardiovascular management.
Japan Coronary Artery Bypass Graft (CABG) Surgery Products Market Size and Forecast
|
Report Attribute |
Details |
|
Base Year Market Size (2026) |
USD 133,819.86 thousand |
|
Forecast Year Market Size (2036) |
USD 177,336.80 thousand |
|
CAGR (2026-2036) |
2.82% |
Key Coronary Artery Bypass Graft (CABG) Surgery Products Market Players:
- Getinge AB (Sweden)
- Terumo Cardiovascular Systems Corporation (U.S.)
- Medtronic (Ireland)
- LeMaitre Vascular, Inc. (U.S.)
- B. Braun SE (Germany)
- Johnson & Johnson (U.S.)
- Zimmer Biomet Holdings, Inc. (U.S.)
- Scanlan International, Inc. (U.S.)
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Getinge AB is a Sweden-based global medical technology company with a strong position in cardiac and cardiovascular care. Its portfolio includes cardiopulmonary products, heart-lung machines, oxygenators, perfusion systems, and operating-room technologies relevant to CABG procedures. The company competes through technological innovation, clinical performance, product reliability, and a broad international distribution network. Its cardiac-surgery business benefits from established relationships with hospitals and specialized cardiac centers, while continued development of extracorporeal and surgical technologies supports its competitive position.
- Terumo Cardiovascular Systems Corporation is a U.S.-based subsidiary of Japan-headquartered Terumo Corporation and focuses on technologies for cardiac and vascular surgery. Its portfolio includes cardiopulmonary bypass systems, perfusion products, oxygenators, cannulae, and other products used during CABG procedures. The company benefits from Terumo's global manufacturing, research, and distribution capabilities. Its competitive strategy emphasizes innovation in cardiac surgery, improved perfusion performance, procedural efficiency, and patient safety, supported by strong relationships with cardiac surgeons and hospitals worldwide.
- Medtronic is a global medical technology company with a broad cardiovascular portfolio and substantial presence across cardiac and vascular care. Its CABG-relevant products span surgical instruments, cardiovascular devices, and technologies supporting cardiac procedures. The company's competitive strength comes from its extensive R&D capabilities, global manufacturing footprint, clinical evidence, and relationships with hospitals and healthcare professionals. Medtronic continues to invest in minimally invasive technologies, procedural efficiency, and cardiovascular innovation. Its broad geographic presence enables the company to serve mature as well as emerging cardiac-care markets.
- LeMaitre Vascular is a U.S.-based medical device company specializing primarily in products for vascular surgery. Its portfolio includes vascular grafts, vessel-harvesting products, surgical instruments, and other technologies that have applications across vascular and cardiovascular procedures. The company competes through specialized product expertise, targeted innovation, strategic acquisitions, and close relationships with vascular and cardiac surgeons. Its focused portfolio differentiates it from diversified medical technology companies. Expansion of its product range and international distribution network supports opportunities to strengthen its position in cardiovascular surgical markets.
- B. Braun SE is a Germany-based global healthcare company offering products across surgery, vascular care, infusion therapy, anesthesia, and other medical fields. Its broad surgical and cardiovascular portfolio gives it relevance to CABG procedures through products used in operative and perioperative care. B. Braun's competitive advantages include extensive manufacturing capabilities, strong quality standards, global distribution, and established hospital relationships. The company emphasizes product innovation, integrated healthcare solutions, and expansion across international markets. Its diversified portfolio allows it to participate in multiple stages of hospital-based cardiac care.
Here is a list of key players operating in the coronary artery bypass graft surgery products market:
The global coronary artery bypass graft surgery products market is characterized by the strong presence of both regional and international companies. The key players are investing heavily in R&D activities to introduce next-gen solutions. Leading companies are competing through product innovation, portfolio expansion, clinical evidence, and strategic acquisitions. Gigantic companies are expanding their operations across high-potential markets to earn lucrative returns. Both organic and inorganic marketing strategies are set to double their revenue shares in the years ahead.
Corporate Landscape of the Global Coronary Artery Bypass Graft (CABG) Surgery Products Market:
Recent Developments
- In April 2026, MicroPort Coronary announced that three key products—the Firehawk and Firehawk Liberty sirolimus-eluting stent systems and the Firefighter NC balloon catheter—received EU MDR certification in March 2026, meeting the bloc’s latest medical-device standards.
- In May 2025, CytoSorbents shared EuroPCR findings showing that its blood-filtering treatment may lessen severe bleeding during urgent bypass operations for patients taking ticagrelor who could not wait for the usual pre-surgery medication washout period.
- Report ID: 8762
- Published Date: Sep 24, 2026
- Report Format: PDF, PPT
- Explore a preview of key market trends and insights
- Review sample data tables and segment breakdowns
- Experience the quality of our visual data representations
- Evaluate our report structure and research methodology
- Get a glimpse of competitive landscape analysis
- Understand how regional forecasts are presented
- Assess the depth of company profiling and benchmarking
- Preview how actionable insights can support your strategy
Explore real data and analysis
Frequently Asked Questions (FAQ)
About this Report
Connect with our Expert
Report, 2027-2036
Copyright @ 2026 Research Nester. All Rights Reserved.
